XML 73 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Indebtedness (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of debt
Total borrowings outstanding are summarized as follows (in millions):
Year Ended
December 31, 2022December 31, 2021
Term loan
2019 Term loan due August 15, 2022 (1)
$— $600.0 
2022 Term loan A due April 1, 2027 (3)
493.8 — 
2022 Term loan B due April 1, 2029 (3)
1,094.5 — 
$1,588.3 $600.0 
Notes and bonds
CouponDue
5.105%
July 28, 2023(1,2)
— 153.5 
4.000%
November 15, 2023(1,6)
— 215.6 
3.900%
December 15, 2024(4)
700.0 700.0 
4.375%
March 15, 2026(7)
700.0 700.0 
4.400%
June 15, 2030(5)
750.0 750.0 
5.300%
November 15, 2043(6)
90.5 90.5 
4.900%
December 15, 2044(4)
303.9 303.9 
Total notes and bonds2,544.4 2,913.5 
Other financing20.6 25.8 
Unamortized premium (discount), net(15.9)(4.8)
Deferred financing fees(30.8)(14.0)
Total borrowings outstanding4,106.6 3,520.5 
Current indebtedness(36.2)(603.8)
Total long-term debt less current portion$4,070.4 $2,916.7 
(1)    Redeemed in connection with the New Senior Secured Credit-Facilities entered into during the second quarter of 2022
(2)    Debt assumed from Omega Pharma Invest N.V., ("Omega") denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.
(3)    Discussed below collectively as the "New Senior Secured Credit Facilities"
(4)    Discussed below collectively as the "2014 Notes"
(5)    Discussed below as the "2020 Notes". The coupon rate noted above is that as of December 31, 2022 following a step up in rate from 3.900% to 4.400% starting after June 15, 2022.
(6)     Discussed below collectively as the "2013 Notes
(7)    Discussed below as part of the "2016 Notes"
Schedule of maturities of short-term and long-term debt
The annual future maturities of our short-term and long-term debt, including capitalized leases and excluding deferred financing fees, are as follows (in millions):
Payment DueAmount
2023$36.2 
2024739.5 
202539.5 
2026739.5 
2027411.3 
Thereafter2,187.3